We used two different cohorts to explore the impacts of ARID1A mutations on CRC and found that ARID1A‐mutated CRCs tended to have higher mutational loads and that ARID1A‐deficient CRCs were more likely to be accompanied by enhanced PD‐L1 expression by stromal cells. The gene discussed is ARID1A; the disease is colorectal carcinoma.